GenesisCare Appoints Seven Leading Oncologists to Chair its Global Research Committees
GenesisCare launches new committees to expand its global research enterprise
Sydney, Australia – GenesisCare, one of the largest oncology providers in the United States, Australia, Spain, and the United Kingdom, today announced the appointment of seven of its outstanding oncologists to chair its newly established Global Research Strategy Committees.
The chairs of these six Global Research Strategy Committees will drive and expand GenesisCare’s research programs globally, working closely with its Contract Research Organisation (CRO) and Site Research Organisation (SRO) to explore and execute new areas of cancer research.
These committees will identify and develop new research projects and partnership opportunities and will work with GenesisCare’s Clinical Reference Groups to develop a research strategy based on clinical needs and opportunities. These committees will foster and develop a world-class network of investigators and support GenesisCare physicians in gaining the skills required to be effective and active investigators.
Global Chief Medical Officer for GenesisCare, Dr. Wally Curran, said: “Our newly formed Global Research Strategy Committees will provide strong strategic direction as we expand our research partnerships and activities globally.”
“Our newly appointed chairs are all global leaders in research and have extensive experience as principal investigators of clinical trials across the full spectrum of oncology research.”
Senior Vice President of GenesisCare’s Research and Insights Division, Kris Barooshian, said: “Physician-led research and development is a key pillar of our research strategy and is critical as our doctors are at the core of patient care and can see the challenges and outcomes gaps which need to be addressed through research.”
GenesisCare has more than 350 cancer care centers globally, access to a world-class team of clinical investigators, long-standing partnerships with leading academic institutions, and a host of proprietary tools for real world data research.
“In a time where much of the world’s research into non COVID-19 related health issues has stood still, GenesisCare has expanded its research infrastructure to ensure the continuity of potentially life-saving research opportunities for cancer patients,” continued Ms Barooshian.
“The establishment of our new Global Research Strategy Committees, led by our world-renowned physicians, is critical as we enter the next phase of in our research growth,” concluded Ms Barooshian.
The Chairs of the Global Research Strategy Committees are as follows:
Professor Nick Pavlakis, Medical Oncologist, Australia – Global Lung Cancer Research Strategy Committee
Professor Pavlakis has extensive experience in clinical research leadership in national and global clinical trials for patients with lung cancer and is actively involved in several collaborative research organisations and advocacy organisations. Professor Pavlakis is the current Board Chair of Thoracic Oncology Group of Australia (TOGA) and is a Committee and Faculty Member with the International Association for the Study of Lung Cancer, a global multidisciplinary organisation dedicated to eradicating lung cancer.
Dr Frank Vicini, Radiation Oncologist, United States – Global Breast Cancer Research Strategy Committee
Dr Frank Vicini, is a world-renowned breast cancer researcher and professor, having authored over 300 peer reviewed articles, presenting his research at national and international meetings. Dr Vicini holds multiple academic appointments and has designed and carried out numerous clinical trials to evaluate new and improved approaches to the care of women with early stage breast cancer including several NCI designated phase III trials that have led to new standards in the treatment of breast cancer.
Dr James Good, PhD, Clinical Oncologist, United Kingdom – Global Gastrointestinal (GI) Cancer Research Strategy Committee
Dr James Good is a leading clinical oncologist in the UK and has led the implementation of MRI-guided radiotherapy for GI cancers there, with a particular focus on pancreas and liver SBRT. Dr Good also has an interest in drug/radiation combination studies. He is currently on the trial management group of the phase 3 CompARE trial, and is deputy chief investigator for the WISTERIA trial and UK chief investigator on the GRECO-2 study.
Professor Andrew Protheroe is an Associate Professor of Uro-Oncology and Consultant Medical Oncologist at the University of Oxford Department of Oncology and holds a PhD in immunology (immune reconstitution following high dose chemotherapy) from St James’s University Hospital in Leeds. He also serves as the physician leader of GenesisCare’s research efforts in the UK.
Dr Thomas Boike, Radiation Oncologist, United States – Global Skin Cancer Research Strategy Committee
Dr Thomas Boike, is a Radiation Oncologist and an Assistant Professor at the University of Texas Southwestern and an Adjunct Assistant Professor at Wayne State University. Dr Boike is passionate about oncology quality in clinical practice and research and is actively involved in several clinical trials.
Professor Nat Lenzo, Nuclear Medicine Physician, Perth, Australia – Global Theranostics Research Strategy Committee
Professor Nat Lenzo is a leading nuclear medicine physician and researcher and is interested in new molecular imaging and targeted therapeutic agents in neurosciences and oncology. Professor Lenzo is the co-investigator on a number of grants, a principal investigator in several multicentre clinical trials, and has co-authored more than 50 peer reviewed publications. Professor Lenzo is an Adjunct Clinical Professor in Medicine at The University of Notre Dame and Curtin University in Perth.
